- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Allergan investigates needle-free Botox method
Drugmakers American Medical Systems and Allergan will be jointly developing and seeking regulatory approval for a version of Botox (onabotulinumtoxinA) using the JetTouch system to treat overactive bladder.
Chadds Ford, Pa. - Drugmakers American Medical Systems and Allergan will be jointly developing and seeking regulatory approval for a version of Botox (onabotulinumtoxinA) using the JetTouch system to treat overactive bladder.
JetTouch is AMS’s injection platform that allows needle-free injection via endoscopic or percutaneous access. Under the companies’ co-development agreement, AMS first will develop JetTouch for general use in the bladder.
If the Food and Drug Administration approves Botox as a treatment for overactive bladder, AMS will work with Allergan to add Botox to the JetTouch label, PRNewswire reports. Allergan plans to seek regulatory advice to add the delivery of Botox with JetTouch to the Botox label.
The FDA approved Botox in August 2011 for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition.
Go back
to the
Dermatology Times eNews
newsletter.
